Metastatic Hormone Refractory Prostate Cancer Completed Phase 2 Trials for Sipuleucel-T (DB06688)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed2 IdentifierTitlePurposeDrugs
NCT02159950Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment
NCT01487863Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerBasic Science
NCT01560923Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate CancerTreatment
NCT01981122A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerBasic Science